Gilbert Amelio Net Worth

The estimated Net Worth of Gilbert F Amelio is at least $1.03 Million dollars as of 11 January 2021. Gilbert Amelio owns over 60,000 units of Galectin Therapeutics Inc stock worth over $166,082 and over the last 14 years he sold GALT stock worth over $682,620. In addition, he makes $181,098 as Independent Director at Galectin Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Gilbert Amelio GALT stock SEC Form 4 insiders trading

Gilbert has made over 10 trades of the Galectin Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 60,000 units of GALT stock worth $130,200 on 11 January 2021.

The largest trade he's ever made was exercising 103,750 units of Galectin Therapeutics Inc stock on 21 January 2019 worth over $185,713. On average, Gilbert trades about 5,081 units every 68 days since 2011. As of 11 January 2021 he still owns at least 60,614 units of Galectin Therapeutics Inc stock.

You can see the complete history of Gilbert Amelio stock trades at the bottom of the page.

Gilbert Amelio biography

Dr. Gilbert F. Amelio M.D. Ph.D. serves as Independent Director of the Company.D. serves as Independent Director of the Company. He currently serves on the boards of Oncofusion Therapeutics and MedsynBio LLC of Ann Arbor, MI. Dr. Omenn is the Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health and Director of the university-wide Center for Computational Medicine and Bioinformatics at the University of Michigan. Dr. Omenn served as executive vice president for medical affairs and as chief executive officer of the University of Michigan Health System from 1997 to 2002. Prior, he was dean of the School of Public Health and Community Medicine and professor of medicine and a Howard Hughes Medical Institute investigator at the University of Washington and Member of the Fred Hutchinson Cancer Research Center. Earlier he was Associate Director of the White House Office of Science and Technology Policy and of the Office of Management and Budget. He is the author of 600 research papers and scientific reviews and author/editor of 18 books. Dr. Omenn received his B.A. summa cum laude from Princeton University, M.D. magna cum laude from Harvard Medical School, and Ph.D. in genetics from the University of Washington. Omenn’s qualifications to sit on our Board of Directors include his extensive executive leadership and management experience in the medical industry and his continuing cutting-edge research.

What is the salary of Gilbert Amelio?

As the Independent Director of Galectin Therapeutics Inc, the total compensation of Gilbert Amelio at Galectin Therapeutics Inc is $181,098. There are 8 executives at Galectin Therapeutics Inc getting paid more, with Harold Shlevin having the highest compensation of $1,306,510.

How old is Gilbert Amelio?

Gilbert Amelio is 78, he's been the Independent Director of Galectin Therapeutics Inc since 2009. There are 1 older and 18 younger executives at Galectin Therapeutics Inc. The oldest executive at Galectin Therapeutics Inc is Gilbert Omenn, 79, who is the Independent Director.

Insiders trading at Galectin Therapeutics Inc

Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr, and Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.

What does Galectin Therapeutics Inc do?

galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much

Complete history of Gilbert Amelio stock trades at Galectin Therapeutics Inc, Interdigital Inc, AT&T, and AT&T

Galectin Therapeutics Inc executives and stock owners

Galectin Therapeutics Inc executives and other stock owners filed with the SEC include:

• Harold Shlevin,
  Director
• Jack Callicutt,
  Chief Financial Officer, Secretary
• Dr. Pol F. Boudes M.D., Ph.D.,
  Chief Medical Officer
• Dr. Pol F. Boudes,
  Chief Medical Officer
• Joel Lewis,
  Pres, CEO & Director
• Kevin Freeman,
  Independent Director
• Joel Lewis,
  President, Chief Executive Officer, Director
• Richard Uihlein,
  Independent Chairman of the Board
• Gilbert Amelio,
  Independent Director
• Gilbert Omenn,
  Independent Director
• Kary Eldred,
  Independent Director
• Eliezer Zomer,
  Executive Vice President - Manufacturing and Product Development
• Marc Rubin,
  Independent Director
• James Czirr,
  Director
• Richard Zordani,
  Independent Director
• Elissa Schwartz,
  Independent Director
• Pol Boudes,
  Chief Medical Officer
• J. Rex Horton,
  Executive Director - Regulatory Affairs and Quality Assurance
• Adam Allgood,
  Executive Director of Clinical Development
• Beth Knowles,
  Exec. Assistant & Officer Mang.
• Robert Tritt,
  Gen. Counsel
• Jack W. Callicutt CPA, CPA,
  CFO, Treasurer & Sec.
• Theodore Daniel Zucconi,
  Director
• John F Mauldin,
  Director
• Fund, L.P.10 X Capital Mana...,
  
• Steven Prelack,
  Director
• Arthur Greenberg,
  Director
• Khurram Jamil,
  Chief Medical Officer
• Benjamin Sr Carson,
  
• Stephen Shulman,
  Director
• Fund, L.P.10 X Capital Mana...,
  
• Peter G Traber,
  CEO and President
• Herman Paul Pressler,
  Director
• Thomas Mcgauley,
  Chief Financial Officer
• Rod D Martin,
  Director
• Jerald K Rome,
  Director
• Fund, L.P.Czirr James C10 X...,